An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study.
An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study.